Relay Therapeutics director SVF Pauling (Cayman) sells $116.4m By Investing.com

SVF Pauling (Cayman) Ltd, a 10% owner and director of Relay Therapeutics, Inc. (), reported the sale of common stock totaling approximately $116,399,999. The transaction occurred on August 25, 2026.

The firm disposed of 6,000,000 shares of common stock at a price of $19.4 per share. Following this transaction, SVF Pauling (Cayman) Ltd beneficially owns 21,904,963 shares of Relay Therapeutics common stock indirectly.The sale comes after a remarkable 426% stock price surge over the past year, bringing the company’s market capitalization to $4.26 billion. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate, which may have influenced the timing of this significant divestment. The platform offers 12 additional ProTips for RLAY investors seeking deeper insights into the company’s outlook.

According to the filing, the securities are held of record by SVF Pauling (Cayman) Limited, which is a wholly owned subsidiary of SoftBank Vision Fund (AIV M2) L.P. SB investment Advisers (UK) Limited serves as the alternative investment fund manager for AIV M2, responsible for managing investment decisions related to SVF Pauling (Cayman) Limited’s holdings.

In other recent news, Relay Therapeutics reported a second-quarter net loss of $0.41 per share, which was larger than H.C. Wainwright’s estimate of $0.37 per share. The company’s research and development expenses reached $76.5 million, and selling, general and administrative expenses were $14.7 million, both exceeding the firm’s expectations. H.C. Wainwright raised its price target for Relay Therapeutics to $29 while maintaining a Buy rating. Citizens also increased its price target for the company to $26, citing progress in breast cancer treatment development. Guggenheim reiterated its Buy rating with a $26 price target, noting ongoing execution of the Phase 3 ReDiscover-2 study in metastatic breast cancer. Canaccord initiated coverage with a Buy rating and a $29 price target, highlighting the potential of Relay’s lead asset, zovegalisib. JPMorgan also initiated coverage with an Overweight rating and a $28 price target, pointing to zovegalisib as a potential growth driver for the company. These developments reflect a focus on the company’s advancements in cancer treatment and ongoing clinical studies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.